drugset / Trial / NCT00464776
Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study will assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy
Timeline
- Start
- 2005-10
- Primary completion
- 2008-04
- Completion
- —
Outcome
Met primary endpoint
paper Aliskiren 150, 300 and 600 mg daily reduced UAER significantly by 36% (95% CI 17-51), 48% (33-60) and 52% (38-63) PMID 20480132 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aliskiren | Small molecule | 150 mg | — |
| Subject | Aliskiren | Small molecule | 300 mg | — |
| Subject | Aliskiren | Small molecule | 600 mg | — |